Real-time
Euronext Paris
04:20:40 2024-06-12 am EDT
|
5-day change
|
1st Jan Change
|
3.16
EUR
|
+0.80%
|
|
-3.66%
|
-22.83%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
98.53
|
449.8
|
479.7
|
188.5
|
211.5
|
164.2
|
-
|
-
|
Enterprise Value (EV)
1 |
62.8
|
354.2
|
444
|
136.3
|
232.3
|
270.7
|
318.1
|
336.4
|
P/E ratio
|
-2.87
x
|
-11.8
x
|
-9.24
x
|
-3.42
x
|
-1.69
x
|
-1.5
x
|
-2.51
x
|
-3.28
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
14.1
x
|
1,209
x
|
114
x
|
15.4
x
|
12.1
x
|
93.9
x
|
12.2
x
|
7.02
x
|
EV / Revenue
|
8.97
x
|
952
x
|
106
x
|
11.2
x
|
13.3
x
|
155
x
|
23.6
x
|
14.4
x
|
EV / EBITDA
|
-2.19
x
|
-12.7
x
|
-8.66
x
|
-2.46
x
|
-2.32
x
|
-2.38
x
|
-3.93
x
|
-5.57
x
|
EV / FCF
|
-2.2
x
|
-11.5
x
|
-9.22
x
|
-3
x
|
-2.83
x
|
-3.01
x
|
-4.8
x
|
-4.69
x
|
FCF Yield
|
-45.4%
|
-8.72%
|
-10.8%
|
-33.4%
|
-35.4%
|
-33.2%
|
-20.8%
|
-21.3%
|
Price to Book
|
2.38
x
|
4.07
x
|
5.17
x
|
4.15
x
|
-
|
-1.29
x
|
-1.1
x
|
-1.14
x
|
Nbr of stocks (in thousands)
|
26,846
|
38,379
|
40,859
|
42,120
|
51,647
|
52,371
|
-
|
-
|
Reference price
2 |
3.670
|
11.72
|
11.74
|
4.475
|
4.095
|
3.135
|
3.135
|
3.135
|
Announcement Date
|
3/10/20
|
3/4/21
|
2/14/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
6.998
|
0.372
|
4.2
|
12.2
|
17.48
|
1.749
|
13.49
|
23.38
|
EBITDA
1 |
-28.73
|
-27.83
|
-51.27
|
-55.41
|
-100.1
|
-113.6
|
-80.88
|
-60.4
|
EBIT
1 |
-30.31
|
-29.72
|
-51.16
|
-57.11
|
-102.7
|
-104.1
|
-94.16
|
-105.5
|
Operating Margin
|
-433.15%
|
-7,988.71%
|
-1,218.14%
|
-468.11%
|
-587.68%
|
-5,954.94%
|
-697.93%
|
-451.02%
|
Earnings before Tax (EBT)
1 |
-30.22
|
-33.62
|
-49.27
|
-54.29
|
-109.8
|
-128.1
|
-117.3
|
-107.9
|
Net income
1 |
-30.22
|
-33.62
|
-49.64
|
-54.27
|
-110.4
|
-106
|
-94.78
|
-107.9
|
Net margin
|
-431.81%
|
-9,037.37%
|
-1,181.79%
|
-444.87%
|
-631.84%
|
-6,059.32%
|
-702.52%
|
-461.32%
|
EPS
2 |
-1.280
|
-0.9900
|
-1.270
|
-1.310
|
-2.430
|
-2.097
|
-1.250
|
-0.9567
|
Free Cash Flow
1 |
-28.54
|
-30.88
|
-48.16
|
-45.49
|
-82.15
|
-89.97
|
-66.27
|
-71.8
|
FCF margin
|
-407.83%
|
-8,301.61%
|
-1,146.74%
|
-372.86%
|
-470.07%
|
-5,144.19%
|
-491.2%
|
-307.1%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
3/4/21
|
2/14/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019 S2
|
2020 S1
|
2020 S2
|
2021 S1
|
2021 S2
|
2022 S1
|
2022 S2
|
2023 Q2
|
2023 S1
|
2023 Q4
|
2023 S2
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2024 S2
|
---|
Net sales
1 |
5.665
|
1.768
|
0.211
|
0.139
|
4.061
|
0.1
|
12.1
|
1.901
|
1.9
|
15.58
|
15.58
|
1.389
|
1.382
|
3.083
|
1.382
|
1.382
|
3.417
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-25.19
|
-
|
-26.16
|
-24.36
|
-
|
EBIT
|
-9.656
|
-15.66
|
-14.05
|
-23.2
|
-27.97
|
-33.47
|
-23.64
|
-
|
-55
|
-
|
-47.71
|
-
|
-25.19
|
-62.47
|
-26.16
|
-24.36
|
-63.63
|
Operating Margin
|
-170.45%
|
-886.03%
|
-6,660.19%
|
-16,687.05%
|
-688.67%
|
-33,468%
|
-195.39%
|
-
|
-2,894.89%
|
-
|
-306.28%
|
-
|
-1,823.33%
|
-2,025.95%
|
-1,893.33%
|
-1,763.33%
|
-1,862.44%
|
Earnings before Tax (EBT)
|
-9.673
|
-15.66
|
-17.96
|
-22.78
|
-26.49
|
-29.48
|
-24.81
|
-
|
-55.28
|
-
|
-54.54
|
-
|
-
|
-60.82
|
-
|
-
|
-62.15
|
Net income
|
-9.673
|
-15.66
|
-17.96
|
-23.14
|
-26.5
|
-29.47
|
-24.81
|
-
|
-55.27
|
-
|
-55.16
|
-
|
-
|
-60.82
|
-
|
-
|
-62.15
|
Net margin
|
-170.75%
|
-885.69%
|
-8,511.85%
|
-16,644.6%
|
-652.52%
|
-29,466%
|
-205.02%
|
-
|
-2,908.89%
|
-
|
-354.12%
|
-
|
-
|
-1,972.43%
|
-
|
-
|
-1,819.02%
|
EPS
|
-0.3500
|
-0.5200
|
-0.4700
|
-0.6000
|
-0.6700
|
-0.7200
|
-0.5900
|
-
|
-1.310
|
-
|
-1.120
|
-
|
-
|
-0.7700
|
-
|
-
|
-0.6200
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/10/20
|
9/16/20
|
3/4/21
|
9/20/21
|
2/14/22
|
9/22/22
|
3/29/23
|
7/27/23
|
7/27/23
|
3/27/24
|
3/27/24
|
-
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
20.8
|
107
|
154
|
172
|
Net Cash position
1 |
35.7
|
95.6
|
35.7
|
52.2
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.2081
x
|
-0.9372
x
|
-1.903
x
|
-2.851
x
|
Free Cash Flow
1 |
-28.5
|
-30.9
|
-48.2
|
-45.5
|
-82.2
|
-90
|
-66.3
|
-71.8
|
ROE (net income / shareholders' equity)
|
-58.7%
|
-44.1%
|
-49.6%
|
-80.8%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
1.540
|
2.880
|
2.270
|
1.080
|
-
|
-2.430
|
-2.860
|
-2.760
|
Cash Flow per Share
2 |
-1.210
|
-0.9000
|
-1.220
|
-1.080
|
-1.800
|
-0.7000
|
-0.3000
|
-
|
Capex
1 |
0.11
|
0.29
|
0.53
|
0.56
|
0.54
|
2.45
|
1.5
|
10.4
|
Capex / Sales
|
1.53%
|
78.49%
|
12.71%
|
4.6%
|
3.09%
|
140.09%
|
11.12%
|
44.27%
|
Announcement Date
|
3/10/20
|
3/4/21
|
2/14/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
3.135
EUR Average target price
13.83
EUR Spread / Average Target +341.25% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.44% | 176M | | +18.34% | 124B | | +15.06% | 109B | | -6.39% | 23.84B | | +2.39% | 22.42B | | -12.11% | 17.5B | | -41.64% | 16.43B | | -12.07% | 16.61B | | +1.05% | 13.4B | | +25.87% | 11.47B |
Bio Therapeutic Drugs
|